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HOW TO DEAL WITH DECISION UNCERTAINTY? THE ITALIAN EXPERIENCE
WITH MANAGED ENTRY AGREEMENTS
Siviero PD, Sammarco A, Tafuri G, Pani L
Italian Medicines Agency, Rome, Italy
OBJECTIVES: To ensure rapid access to new potentially beneficial medicines and
affordability, payers are adopting innovative approaches called Managed Entry
Agreement(MEAs). AIFA has pioneered in the design and implementation of MEAs
for the last two decades. The objective is to describe and quantify AIFA’sMEAs used
to support decision-making in situations of uncertainty.METHODS: Data on MEAs
were retrieved from the AIFA monitoring registries and databases, and analyzed
between August 1st 2011 and December 15th 2011. RESULTS: The management of
uncertainty of new medicines/therapeutic indications(TI) is performed through
arrangements based on access with evidence development i.e. “AIFA monitoring
registries” which can be associated with outcome based schemes: “Payment by
Results(PbR)” or “Risk-Sharing(RS)”. To manage utilization, AIFA set “Restricting
Notes for Prescription”(RNP), a tool to restrict NHS reimbursability of medicines for
a particular condition/disease, and the “Therapeutic Plans”(TP), which guarantee
reimbursement only under specialist monitoring. To achievemanagement of bud-
get impact, financial-oriented schemes are in place: The “Volume-based Agree-
ments”(VbA), a negotiation of volume of sales between AIFA and manufacturers,
and the Cost-sharing(CS), a discount on the initial therapy cycle(s) for all eligible
patients. The AIFA Registries include 78 TI: 44 refer to oncology, 15 to rare diseases,
7 to diabetes and the remaining to other therapeutic areas. Among 78 TI, 14 were
PbR, 12 CS and 2 RS. For the remaining 50 indications, no scheme for reimburse-
ment was applied, but registries were used to monitor post-marketing safety and
effectiveness. Furthermore AIFA implemented 32 RNP and a total of 85 VbA and TP
for more than 350 medicines. CONCLUSIONS: Unlike other European authorities
which base reimbursement decisions on thresholds, AIFA implemented an exten-
sive range of strategies to allowhealth care access and budget sustainability. These
strategies ensure proper utilization of standard therapies and guarantee access to
most recent innovative medicines.
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DEFINING ELEMENTS OF VALUE FOR RARE DISEASE TREATMENTS
Hutchings A1, Ethgen O2, Schmitt C3, Rollet P3
1GMAS, London, UK, 2University of Liege, Liege, Belgium, 3GlaxoSmithKline, London, UK
Rare diseases are an important medical and social issue. Although the prevalence
of individual diseases is by definition low, in aggregate the number of people af-
fected by a rare disease is considerable. These conditions are characterized by
severe, debilitating symptoms that substantially affect life expectancy, physical
and social functioning, and quality of life of patients and their families. The ques-
tion of what constitutes value for rare disease drugs, and how this should be eval-
uated, is central to the successful continuation of the orphan drug market, and to
properly support asset value-based pricing. The objective of this work was to pro-
vide preliminary insight into the elements of value which are important when
assessing rare disease treatments and how they might be considered together
within a value framework. A literature review sought to identify elements of value
that are currently considered by European payers when assessing rare disease
treatments, those described in patient group surveys, and value elements that
have been quantified and described empirically for existing drugs. A generic con-
ceptual value framework was derived based upon the literature review, and this
was tested with rare disease experts, patient group representatives, and payers.
Multiple criteria are considered in assessing the value of rare diseases treatments,
including burden of disease, therapeutic benefit, familial and societal impact, and
economic and budgetary implications. Scientific innovation was also considered,
but primarily as a supporting rationale for therapeutic benefit. Clinical/social out-
come anchored evidence and data uncertainty were seen to be key factors in de-
termining perceived value. In future, payers will need to develop assessment
frameworks that better reflect the societal value of treatments for rare diseases.
This value is perceived throughmultiple domains that are not always incorporated
in current payer mechanisms. Multi-criteria decision analysis offers a possible
construct for incorporating these elements in future.
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LEGAL IMPACT OF PHARMACEUTICAL PRICING IN THE GERMAN STATUTORY
HEALTH INSURANCE SYSTEM
Gissel C
Justus Liebig University Giessen, Giessen, Hessen, Germany
OBJECTIVES: After the failure of the efficiency frontier approach, Germany intro-
duced rebate negotiations for all new drugs in the Statutory Health Insurance
system in 2011. We aim to compare the legal impact of both approaches on consti-
tutional rights. METHODS: We apply a legal analysis with regard to the constitu-
tional rights affected by both approaches. RESULTS: In the new system of negoti-
ating prices, manufacturers are free to negotiate any rebate. However, if the
negotiations do not result in an agreement, an arbitration board determines the
rebate. Themanufacturer cannot directly influence the board’s decision. The board
considers both the drug’s benefit compared to existing drugs and the European
price level as a reference. The board’s decision is binding until a new agreement
has been negotiated. With the efficiency frontier approach, the Statutory Health
Insurance funds set a maximum reimbursable price based on cost-effectiveness
analysis with the efficiency frontier. The manufacturer remains free to charge any
price, resulting in patients’ out-of-pocket payments. In the negotiations system,
the manufacturers lose their economic freedom to exercise the right to offer their
product at any price. In the efficiency frontier system, access to drugs is effectively
rationed for patients despite their membership in the Statutory Health Insurance.
Their constitutional right to life and health is affected. CONCLUSIONS: Assuming
that there is always a difference between the price amanufacturer wants to charge
and the price the Statutory Health Insurance funds want to pay, the legislator
needs to decide who has to cover the economic burden. The legislator faces a
trade-off between manufacturers’ and patients’ constitutional rights. In the Ger-
man constitution, the right to life and health is more important than economic
freedom.
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FROM VALUE TO PRICE: WHAT SHOULD BE THE PATH FOR ORPHAN DRUGS?
Ethgen O1, Hutchings A2, Rollet P3, Standaert B4
1University of Liege, Liege, Belgium, 2GMAS, London, UK, 3GlaxoSmithKline, London, UK,
4GlaxoSmithKline Biologicals, Wavre, Belgium
Setting an appropriate price for an innovative orphan drug is increasingly difficult
in today’s resource constrained health care systems.What constitutes the value of
orphan drugs is mainly perceived as empirical and a function of their rarity. The
conventional cost-effectiveness (CE) approach analysis implies the use of a CE
threshold. The determination of this threshold for orphan drugs is a contrived
exercise and can make the pricing decision hard to justify in the eyes of many
stakeholders, notably clinicians and patients. In this conceptual research, we ex-
plore the use of a value-based pricingmathematical function to link the incremen-
tal value brought by innovative orphan drugs to their prices. This function depicts
the incremental value-based price (Y-axis) against the incremental value (X-axis).
Value is holistically considered and embraces multiple clinical, humanistic and
societal criteria that can be weighted by stakeholders (clinicians, patients, caregiv-
ers and payers). The incremental value is thus assessed throughout multi-criteria
decision analysis (MCDA) and is finally embodied into a unified value score. The
value-based price is expressed as a function of this value score. The exact shape of
this value-based pricing function is obviously unknown. However, we stipulate
that it has to satisfy two necessary conditions:) growing, and 2) bounded by the
maximumwillingness-to-pay (WTP) for the ultimate achievable incremental value
(e.g. cure of the disease).We compare two functional forms: linear and sigmoid and
we debatemultipleWTP scenarios and perspectives. Finally, we conclude that this
simple and transparent mathematical approach might prove useful to inform val-
ue-based pricing. When combined with MCDA, the approach makes more explicit
the relevant value determinants and incorporates these determinants in a more
holistic value and pricing framework for rare disease treatments. Empirical works,
however, are needed to further substantiate the approach in the eyes of decision
makers.
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VALUE BASED PRICING IN THE UNITED KINGDOM - LET US PREPARE FOR IT !
Mukku S
Double Helix Consulting Group, London, UK
OBJECTIVES: The importance given to different domains of decisions differ by
markets around the world. The research is aimed to analyse how perspectives on
value assessment of pharmaceuticals or device interventions vary across markets
and how it is likely to be implemented in the United Kingdom. The research also
analysed how products at launch increase the chances of approval, shorten time to
reimbursement and remain competitive within the value based pricing agenda.
METHODS: The research was conducted through indepth secondary research and
interviews with stakeholders in the United Kingdom and selected markets (Aus-
tralia, Sweden and The Netherlands) RESULTS: The research indicated that most
countries, other than those that use international price referencing for setting
prices use some formof value assessmentmethod before fixing the reimbursement
level and price of the product. The decisions are predominantly based on level of
unmet needs, severity of diseases, level of innovation, clinical differentiation of the
new product against its comparators and how well the product finds it natural
place in the treatment pathway. Many forward regions claim to use value based
assessments to set the price of new launches, most operate within boundaries. In
principal value based pricing should not be fenced with limitations such as cost/
QaLY thresholds, budget impact and price-volume agreements. In real life, how-
ever, financial impact becomes one of the key influencing factors and is expected to
dominate in the near future too. CONCLUSIONS: It is difficult to assess the true
value of a product at launch and it is difficult for both, the health authorities who
have limited budgets and pharmaceutical industry which spends enormous
amounts to bring products to market. VBP, however, could be the most suitable
solution for the UK. If successful international markets may adopt it or refer to UK
recommendations on new launches for their respective decisions.
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POTENTIAL IMPLICATIONS OF NATIONAL DISEASE REGISTRIES AND CENTERS
OF EXCELLENCE FOR ORPHAN DISEASES FOR PHARMACEUTICAL
MANUFACTURERS DEVELOPING ORPHAN DRUGS
Dobrovolny D, Patel A, Dalsania R, Paas M
Bridgehead International Ltd, New York, NY, USA
BACKGROUND: Recent recommendations from the EU commission have given
countries the responsibility to develop national strategies for rare diseases, includ-
ing plans for inventorying of rare diseases and development of centers of excel-
lence (CoE). In France, patients are required to consult or obtain their prescription
from a CoE in order for reimbursement of orphan drugs to be granted. As CoE and
rare disease registries are developed throughout the EU member states, increased
awareness, education, and data collection will lead to better management of or-
phan diseases, monitoring of long-term outcomes and cost and opportunities for
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payer management. OBJECTIVES: To better understand the current and evolving
roles of CoE and national disease registries in the EU, including implications on the
price and management of orphan drugs, and to identify implications for further
evolution of rare disease specialty centers in theUS. Trends on the EUdevelopment
of CoE and national rare disease registries will be reviewed and expert opinion will
be consulted. RESULTS: Tools and data that will be available to both the payer
bodies and the CoE will be identified Examples of influence of CoE and disease
registries on the pricing and reimbursement of orphan drugs (e.g. CoE in France,
cancer registries in Italy) will be described. Implications of the use of this informa-
tion and data will be explored for EU payers. CONCLUSIONS: EU payer bodies will
gain increasing information and data necessary to further scrutinize the price and
reimbursement opportunity for orphan drugs, through the use of registries and
evaluation by CoE. Manufacturers should be prepared to understand and consider
partnerships with CoE in EU.
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A REVIEW OF DIFFERENT APPROACHES PROPOSED FOR VALUE BASED PRICING
Hawkins N1, Scott DA1, Moore P2
1Oxford Outcomes, Oxford, UK, 2Oxford Outcomes, Vancouver, BC, Canada
Decision makers who undertake health technology assessments such as those
conducted by NICE, deliberatively consider a new technologies cost per QALY,
alongside other criteria (such as, equity, whether treatment is lifesaving and pa-
tient experience, etc) which are not captured in incremental cost-effectiveness
ratios alone. The intention to implement an explicit value based pricing scheme in
theUnitedKingdom in 2014 has sparked a debate regardingwhich elements should
be included in the assessment of value and how they should be combined and
traded-off against each other. Of importance is consideration to how values should
be derived to determine how different criteria should trade-off each other. This
debate is timely given that even where price is considered to be fixed during the
re-imbursement process (such as the current NICE process) such systems could be
seen implicitly determining value based price andmay influence pricing decisions.
Using an example presented in a recent review or multi-criteria decision making
(Thokala 2011) we compare four mechanisms by which different elements of
value could be explicitly and deterministically traded-off in order to provide an
overall estimate of a value based price.The mechanisms are:conventional cost
per QALY; MCDA; adjusted QALY approach; adjusted threshold approach; and a
net benefit approach. Hypothetical criteria incorporated into the decision mak-
ing process include equity, innovation, patient compliance and the quality of
evidence. Using these examples, we show that thesemethods are clearly related
in that they ultimately require estimates of monetary value to be placed on each
dimension of value, but may place different emphasis on the weightings given
to specific elements and the potential interactions between different elements.
The mechanism in which these monetary values are derived, must importantly
reflect societies values in trading off additional criteria for overall health gains.
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PRIORITY SETTING FOR HEALTH TECHNOLOGY ASSESSMENT IN UKRAINE
Pariy V1, Stepanenko A2, Mandrik O3, Zalis’ka O3
1Bogomolets National medical University of Ukraine, Kyiv, Ukraine, 2The State Expert Center of
the Ministry of Health of Ukraine, Kyiv, Ukraine, 3Danylo Halytsky Lviv National Medical
University, Lviv, Ukraine
OBJECTIVES: Under the concept of pharmaceutical branch development (2011-
2020), social reimbursement system is going to be developed and implemented in
Ukraine. That will demand a use of central health technology assessment (HTA)
approach with appropriate instruments for its implementation. The aim of this
publication was to develop an instrument for HTA prioritization in Ukraine by
using qualitative approach. METHODS: A literature search was performed across
PudMed, Medline, and Cochrane. EUR-ASSESS report was analyzed. Factors impor-
tant for current health care decision making, data availability, and criteria impor-
tant for prioritization in the other countries were reviewed by the experts and
assessed on their applicability in Ukrainian health care setting. RESULTS: A list of
criteria that should be a basis for HTA prioritization in Ukraine was developed. The
criteria have different weight in accordance to their importance and data availabil-
ity. These criteria are the following: burden of disease, current size of state financ-
ing for this health care branch, potential benefit of intervention for individual
patient, disease prevalence, direct cost of intervention per patient, estimated bud-
get impact, current rate of the technology use, inclusion of a medical product into
standardized documents (clinical protocols, State formulary), additional aspects
with an impact on health policy. CONCLUSIONS: Factors important for HTA prior-
itization in the other countries can not be used without adaptation due to differ-
ences in health care systems, current decision-making processes, and data avail-
ability. Developed prioritization instrument should be used as a tool for future
health care insurance system in Ukraine.
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NEED AND IMPORTANCE OF PHARMACOECONOMIC GUIDELINES IN INDIA
Udupa DN1, Janodia M2, Muragundi PM1
1Manipal College of Pharmaceutical Sciences, Manipal, Karnataka, India, 2Manipal University,
Manipal , Karnataka, India
India’s health care requirements are different as different systems of medicine are
practiced. Only 15-20% of India’s population has access to modern medicines (all-
opathic medicines) whereas remaining population uses traditional systems such
as Ayurveda, Siddha, Unani, home remedies etc. People who have access to mod-
ern medicines have to spend out of pocket expenditure in order to have access to
health care facilities including hospital, diagnosis and medicines. Out of these
medicines are important for overall wellbeing population. Moreover only 10 % of
population is covered by health financing schemes including medical insurance.
Further a more than 1lakh (0.1 million) different brands of medicines flourish
Indian market with sometimes more than a 100 brands of same molecule. The
problem is manufacturers charge different prices for different brand names of
same molecule. Medical practitioners have various options to choose from to
prescribe these medicines and many a times it is observed that patients are
given costly medicines when they can be given an economical alternative. This
leads to financial burden on patients and health financing schemes including
private and public sector. This is due to a lack of standard pharmacoeconomics
guidelines in India. In presence of pharmacoeconomics guidelines it would be
simpler to identify an economical alternative that would be beneficial to patient
in particular and to society at large. In Asia countries like China, Taiwan, South
Korea, Thailand have taken steps in formulating pharmacoeconomics guide-
lines. Even other developing countries like South Africa, Brazil, Mexico have
taken steps to implement pharmacoeconomics guidelines. Country like India
should take proactive steps in order to design and implement pharmacoeco-
nomics guidelines.
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ANALYZING THE NEW ERA OF NATIONAL COVERAGE DETERMINATIONS
(NCD’S) BY THE CENTERS FOR MEDICARE & MEDCAID SERVICES (CMS) POST ITS
SIPULEUCEL-T DECISION
Stevens CA, Miller KL
PAREXEL Consulting, Waltham, MA, USA
OBJECTIVES: To review the various options that the Centers for Medicare & Med-
icaid Services (CMS) has to review new drugs and biologics under its National
Coverage Determination (NCD) process, and conduct such review in the wake of its
recent NCD for sipuleucel-T. This analysis seeks to better understand if CMS will
employ NCD’s to centralize its control over drug coverage.METHODS: NCD’s have
primarily been applied to drugs and devices that have had some associated issue
that could result in productmisuse. Suchmisusemay lead to unwarranted use, use
that increases costs without commensurate outcomes, us that may impact patient
safety or use outside of indication that is not deemed reasonable and necessary.
Review of the most recent CMS NCD covering sipuleucel-T provides some indica-
tion as to how CMS may use its NCD authority to control product coverage.
RESULTS:Analysis of past CMSNCD’s indicates that CMShas historically regulated
devices under NCD at a greater rate than drugs or biologics when there has been a
concern over unwarranted use that would increase product utilization and costs
over existing products. This has resulted in coverage and payment being either
restricted or tied to other products. In the case of sipuleucel-T, CMS subjected it to
review under NCD due to the fact that it is a vaccine, its cost is high and the high
potential for use outside of castration resistant prostate cancer as reported in the
media. The result of CMS’ review was an NCD that allowed for coverage of on label
use of sipuleucel-T, but reserved off label coverage decisions to individual
contractors. CONCLUSIONS: Using CMS’ sipuleucel-T NCD as a potential predictor
of future NCD actions, CMS may continue to make overall coverage decisions re-
garding labeled indications, but defer off label coverage determinations to local
contractors.
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DIFFERENTATIATOR FOR THE FUTURE: HEALTH TECHNOLOGY
ENVIRONMENTAL FOOTPRINTS
Wright AJ, Froehlich HJ
PHMR Associates, London, UK
OBJECTIVES: A survey was conducted to establish the extent to which environ-
mental factors impact payers and payer influencers, aswell asmacro-environmen-
tal policy and purchasing decisions. METHODS: Qualitative telephone interviews
were undertaken with subjects in the UK, Germany, France, Spain and Sweden.
RESULTS: Though still in their infancy, environmental consequences were con-
firmed as becoming an important dimension of health technology assessment
(HTA). Regulation and best practice guidelines designed to limit the environmental
impact of purchasing strategy were identified at local, regional, or national level in
Sweden and the UK. Poor data availability was identified as a major challenge,
undermining the credibility of claims related to environmental factors. To avoid a
“green-wash” of health technologies presented to decision makers along the value
chain, environmental evaluations will need to provide robust, standardized infor-
mation concerning a wide range of criteria, such as waste management, energy
containment or Carbon footprints. Health technology development, aswell asmar-
ket accessmanagement will have to anticipate an evolving awareness for environ-
mental matters, in both emerging and mature markets. Their ultimate translation
into policy and regulation is anticipated to be a combination of regulatory control
and progressive application of Pigovian costs.CONCLUSIONS: Regulatory control is
likely to be rolled out through updated operating procedures in existing structures,
such as public agencies in charge of homologation, HTA or reimbursement. This is
not likely to happen in a consistent manner across the various national healthcare
systems. Payers are expected to deal not only with evolving enhanced recommen-
dations and standards, but might choose to pro-actively reflect environment-re-
lated viewpoints themselves, when defining future specifications. In such a sce-
nario, strategic purchasers will encounter a framework of versatile requirements
and incentives, and are likely to opt for health technologies that are able to present
a solid environmental case.
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